Ariad reiterated at market outperform by JMP

Ariad Pharmaceuticals, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at market outperform. The company's financial results meet expectations, and it remains focused on advancing the clinical development of AP573 in 2006. Total revenues of $242,000 were slightly lower than JMP's and consensus estimates of $300,000, but net loss per share of $0.23 modestly beat JMP's and the Street's expectations of $0.24 and $0.25. Shares of the Cambridge, Mass., pharmaceutical company were up 5 cents, or 0.87%, at $5.83 on volume of 645,844 shares versus the three-month running average of 616,340 shares. (Nasdaq: ARIA)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.